A median overall survival of 16.0 months was achieved with trastuzumab plus chemotherapy in patients with higher HER2 expression levels [12], which compares favorably with previous studies of chemotherapy-only regimens in advanced gastric cancer [28, 29]. The gene discussed is ERBB2; the disease is gastric cancer.